Randomized phase II study of CPT-11 plus TS-1 plus Cetuximab for advanced and/or recurrent colon cancer which are oxaliplatin-resistant and KRAS wild type (OGSG 0901) - OGSG 0901

Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)0 个研究点目标入组 35 人开始时间: 2009年10月31日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) with treatments including CPT-11 and/or Cetuximab 2) with active double cancers 3) Any other serious illness or medical condition(s) including ileus, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, heart failure, renal failure, liver failure, etc. 4) Infectious disease 5) Diarrhea (watery stools) 6) with obstruction or disorder on digestive tract due to peritoneal metastasis 7) with ascites and/or pleural fluid 8) History of serious drug hypersensitivity 9) Undergoing anti-fungal treatment with fluorocytosine, or atazanavir sulfate. 10) Found to have fresh gastrointestinal bleeding that requires repeated transfusion. 11) With liver cirrhosis or jaundice. 12) patients undergoing treatment with a psychotropic agent or who have a mental disorder that seems to require treatment. 13) having heart disease, such as ischemic heart disease or an arrhythmia, which require treatment. 14) With diabetes that is difficult to control. 15) With central nervous system metastasis 16) women pregnant, breast-feeding, or who wish pregnancy 17) Any other patient whom the physician in charge of the study judges to be unsuitable

发起方

Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)